Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease‐Modifying Antirheumatic Drugs in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis
Open Access
- 24 January 2017
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 69 (5), 932-942
- https://doi.org/10.1002/art.40054
Abstract
Objective To evaluate the efficacy and safety of orally administered once‐daily peficitinib in combination with limited conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs) in patients with moderate‐to‐severe rheumatoid arthritis (RA). Methods In this randomized, double‐blind, phase IIb trial, patients with RA (n = 289) were treated with peficitinib 25 mg, 50 mg, 100 mg, or 150 mg or matching placebo once daily for 12 weeks. The primary end point was the percentage of patients who met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at week 12. Results ACR20 response rates at week 12 were 22.0%, 36.8%, 48.3% (P < 0.05), 56.3% (P < 0.01), and 29.4% in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, respectively. Patients in the peficitinib 100 mg and 150 mg groups achieved a rapid and statistically significant ACR20 response compared with those in the placebo group (P < 0.05), reaching statistical significance by week 2. Overall, the incidence of adverse events (AEs) was similar between patients receiving peficitinib and those receiving placebo. The most common AEs were upper respiratory tract infection (5% [n = 15]), nausea (4% [n = 12]), and urinary tract infection (4% [n = 10]). There was 1 case of herpes zoster in the placebo group, and 1 serious infection (limb abscess) in the peficitinib 25 mg group. There were no incidences of grade 2 or higher neutropenia or lymphopenia. Conclusion In patients with moderate‐to‐severe RA, orally administered once‐daily peficitinib in combination with limited csDMARDs resulted in a dose‐dependent ACR20 response rate over 12 weeks with satisfactory tolerability.Keywords
Funding Information
- Astellas Pharma Global Development
This publication has 18 references indexed in Scilit:
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD studyAnnals Of The Rheumatic Diseases, 2016
- Baricitinib in Patients with Refractory Rheumatoid ArthritisThe New England Journal of Medicine, 2016
- Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double‐blind, phase 3 studyThe Journal of Dermatology, 2016
- Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexateAnnals Of The Rheumatic Diseases, 2014
- Tofacitinib versus Methotrexate in Rheumatoid ArthritisThe New England Journal of Medicine, 2014
- Janus kinase inhibitors in autoimmune diseasesAnnals Of The Rheumatic Diseases, 2013
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trialThe Lancet, 2013
- Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic studyArthritis & Rheumatism, 2013
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid ArthritisThe New England Journal of Medicine, 2012
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid ArthritisThe New England Journal of Medicine, 2012